简短报告：阿巴卡韦是否应成为撒哈拉以南非洲地区成人艾滋病病毒感染者的一线替代药物？
Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?
作者信息
Lee Guinevere Q, McCluskey Suzanne, Boum Yap, Hunt Peter W, Martin Jeffrey N, Bangsberg David R, Gao Xiaojiang, Harrigan P Richard, Haberer Jessica E, Siedner Mark J
机构信息
*BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; †Department of Infectious Diseases, Massachusetts General Hospital, Boston, MA; ‡Harvard University Center for AIDS Research, Harvard Medical School, Boston, MA; §Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda; ‖HIV/AIDS division, University of California, San Francisco, CA; ¶Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA; #School of Public Health, Oregon Health Sciences University, Portland, OR; and **Center for Cancer Research, National Cancer Institute, Frederick, MD.
出版信息
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):188-192. doi: 10.1097/QAI.0000000000001487.
Abstract
Despite a poor toxicity profile, zidovudine supersedes abacavir (ABC) as an alternative first-line agent in most international treatment guidelines because of concerns about HLA-B57:01-related ABC-hypersensitivity. We detected one case of HLA-B57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with previous reports, supports the safety of ABC in the region.
摘要
尽管齐多夫定的毒性特征不佳，但由于担心与HLA - B57:01相关的阿巴卡韦超敏反应，在大多数国际治疗指南中，齐多夫定取代阿巴卡韦（ABC）作为替代一线药物。我们在乌干达513名艾滋病毒感染者中检测到1例携带HLA - B57:01，结合先前的报告，这支持了ABC在该地区的安全性。
相似文献
1
Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?简短报告：阿巴卡韦是否应成为撒哈拉以南非洲地区成人艾滋病病毒感染者的一线替代药物？
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):188-192. doi: 10.1097/QAI.0000000000001487.
2
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.在撒哈拉以南非洲地区，基于齐多夫定的一线抗逆转录病毒治疗出现长期病毒学失败后，HIV-1胸苷类似物突变的快速积累及其表型影响
J Antimicrob Chemother. 2017 May 1;72(5):1450-1455. doi: 10.1093/jac/dkw583.
3
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.北美HIV感染受试者中HLA - B*57:01等位基因的流行率以及等位基因检测对HLA - B*57:01阴性受试者中阿巴卡韦相关超敏反应发生率的影响。
BMC Infect Dis. 2017 Apr 11;17(1):256. doi: 10.1186/s12879-017-2331-y.
4
Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?在开始阿巴卡韦治疗前进行HLA-B*5701基因分型以降低超敏反应：对临床有用，但在新加坡是否具有成本效益？
Pharmacogenet Genomics. 2015 Feb;25(2):60-72. doi: 10.1097/FPC.0000000000000107.
5
Abacavir (Ziagen(®)) use between 2003 and 2008 in France according to the electronic medical record NADIS(®).根据电子病历 NADIS（®），2003 年至 2008 年期间在法国使用阿巴卡韦（Ziagen（®））。
Med Mal Infect. 2013 Dec;43(11-12):467-74. doi: 10.1016/j.medmal.2013.09.012. Epub 2013 Nov 18.
6
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.阿巴卡韦单药及与齐多夫定联合用药在HIV感染成人中的抗逆转录病毒作用及安全性。阿巴卡韦2期临床研究团队。
AIDS. 1998 Nov 12;12(16):F203-9. doi: 10.1097/00002030-199816000-00002.
7
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.奈韦拉平/齐多夫定/拉米夫定与阿巴卡韦/齐多夫定/拉米夫定在随机对照 48 周比较中，在免疫和病毒学应答方面具有优势，但并未反映在临床结局方面，该研究纳入了乌干达低 CD4 细胞计数的 HIV 感染成人。
HIV Med. 2010 May;11(5):334-44. doi: 10.1111/j.1468-1293.2009.00786.x. Epub 2010 Feb 3.
8
Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.齐多夫定/拉米夫定+阿巴卡韦+依非韦伦四联方案用于初治HIV-1感染成人抗逆转录病毒治疗的疗效和安全性：法国研究
J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):178-82. doi: 10.1097/00126334-200210010-00008.
9
High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia.在塞尔维亚感染 HIV 的患者中人类白细胞抗原-B*57:01 等位基因携带者的高频率。
Intervirology. 2017;60(1-2):43-47. doi: 10.1159/000477810. Epub 2017 Aug 4.
10
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.HLA-B*5701、HLA-DR7和HLA-DQ3的存在与对HIV-1逆转录酶抑制剂阿巴卡韦的超敏反应之间的关联。
Lancet. 2002 Mar 2;359(9308):727-32. doi: 10.1016/s0140-6736(02)07873-x.
引用本文的文献
1
Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda.乌干达的A1和D亚型，以及与来那卡帕韦耐药性相关的重组HIV-1自然多态性。
J Antimicrob Chemother. 2025 Apr 2;80(4):955-961. doi: 10.1093/jac/dkaf018.
2
Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa.在西非和中非的 HIV 感染者中人类白细胞抗原 HLA-B*57:01 的流行率。
BMC Immunol. 2021 Jul 22;22(1):48. doi: 10.1186/s12865-021-00427-7.
本文引用的文献
1
Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.肯尼亚西部农村地区急性和近期感染且未接受过抗逆转录病毒治疗的人群中HIV-1 pol传播耐药性的监测
PLoS One. 2017 Feb 8;12(2):e0171124. doi: 10.1371/journal.pone.0171124. eCollection 2017.
2
African partnerships through the H3Africa Consortium bring a genomic dimension to longitudinal population studies on the continent.通过“非洲人类遗传与健康”（H3Africa）联盟建立的非洲伙伴关系，为该大陆的纵向人群研究引入了基因组层面的内容。
Int J Epidemiol. 2016 Apr;45(2):305-8. doi: 10.1093/ije/dyv187. Epub 2015 Dec 10.
3
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.阿巴卡韦、齐多夫定或司他夫定作为非洲感染艾滋病毒儿童的儿科片剂（CHAPAS-3）：一项开放标签、平行组、随机对照试验。
Lancet Infect Dis. 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5.
4
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.简要报告：多替拉韦联合阿巴卡韦/拉米夫定用于初治HIV-1感染患者的抗逆转录病毒治疗：来自SINGLE随机临床试验的第96周和第144周结果
J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9. doi: 10.1097/QAI.0000000000000790.
5
An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.一种用于预测 HIV 阳性人群心血管疾病全球风险的更新预测模型：抗 HIV 药物不良反应数据收集研究（D:A:D 研究）。
Eur J Prev Cardiol. 2016 Jan;23(2):214-23. doi: 10.1177/2047487315579291. Epub 2015 Apr 16.
6
Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations.等位基因频率网络2015年更新：HLA表位、杀伤细胞免疫球蛋白样受体以及疾病与HLA药物不良反应关联的新特征
Nucleic Acids Res. 2015 Jan;43(Database issue):D784-8. doi: 10.1093/nar/gku1166. Epub 2014 Nov 20.
7
Frequencies of immune hypersensitivity reaction-associated HLA class I alleles in healthy South African Indian and mixed ancestry populations determined by a novel real-time PCR assay.通过一种新型实时聚合酶链反应检测法确定健康南非印度裔和混合血统人群中免疫超敏反应相关的HLA I类等位基因频率。
Tissue Antigens. 2014 Oct;84(4):389-97. doi: 10.1111/tan.12414. Epub 2014 Aug 25.
8
Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected cohort in northern South Africa: a pilot study.南非北部一个HIV感染队列中APOC3启动子和HLA - B基因的遗传变异：一项试点研究。
Int J Mol Sci. 2014 Jun 26;15(7):11403-15. doi: 10.3390/ijms150711403.
9
Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda.乌干达传播的HIV-1耐药性的流行情况及病毒学后果
AIDS Res Hum Retroviruses. 2014 Sep;30(9):896-906. doi: 10.1089/AID.2014.0043. Epub 2014 Jul 29.
10
The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy.乌干达开始接受抗逆转录病毒治疗的HIV感染者中色氨酸分解代谢的犬尿氨酸途径、CD4 + T细胞恢复情况及死亡率
J Infect Dis. 2014 Aug 1;210(3):383-91. doi: 10.1093/infdis/jiu115. Epub 2014 Feb 28.
Zotero 插件